ANRO
Alto Neuroscience Inc.

1,126
Loading...
Loading...
News
all
press releases
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
Stocktwits·6d ago
News Placeholder
More News
News Placeholder
Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO
Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO Alto Neuroscience, Inc. Sued for Securities Law Violations...
PR Newswire·2mo ago
News Placeholder
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March
Alto Neuroscience represents a high-risk, high-reward opportunity.
barchart.com·7mo ago
News Placeholder
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.
Stocktwits·7mo ago
News Placeholder
Alto Neuroscience to Participate in Upcoming Investor Conferences
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Business Wire·8mo ago
News Placeholder
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the...
Business Wire·8mo ago
News Placeholder
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple...
Business Wire·10mo ago
News Placeholder
Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline Allink Biotherapeutics Raises $42M Series A Financing to Accelerate...
PR Newswire·11mo ago
News Placeholder
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial...
Business Wire·11mo ago
News Placeholder
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. (Alto Neuroscience or the Company) (NYSE: ANRO...
Business Wire·11mo ago

Latest ANRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.